fig5

Figure 5. mRNA-LNP delivery for LAM treatment^[107]. (A) Schematic of hybrid lipid hLNPs; (B) In vivo fluorescence imaging demonstrating EGFP expression localized in mouse LAM lungs following intravenous injection of EGFP mRNA-loaded hLNPs; (C) Confocal immunofluorescence images showing colocalization of phospho-S6 and EGFP, confirming targeted delivery to tumor cells. LNP: Lipid nanoparticle; LAM: lymphangioleiomyomatosis; DMG-PEG: 1,2-dimyristoyl-rac-glycero-3-methoxy-polyethylene glycol; EGFP: enhanced green fluorescent protein; hLNP: hybrid lipid nanoparticle; pS6: phosphorylated ribosomal protein S6.